ACRIVON THERAPEUTICS INC (ACRV) Stock Earnings & Estimates
USA - NASDAQ:ACRV - US0048901096 - Common Stock
2 USD
+0.01 (+0.5%)
1.9203 USD
-0.08 (-3.99%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 805.34% | N/A 691.78% | N/A 321.81% | N/A 132.56% | N/A 57.38% | N/A 35.59% | N/A 41.31% | ||||||
| EBITDA YoY % growth | -3.16M | -16.14M -410.76% | -32.3M -100.12% | -66.567M -106.09% | -88.193M -32.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.17M | -16.18M -410.41% | -32.66M -101.85% | -67.103M -105.46% | -89.199M -32.93% | N/A -6.55% | N/A -14.30% | N/A -22.70% | N/A -8.08% | N/A 22.31% | N/A 58.01% | N/A 223.97% | N/A 123.54% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.73 60.91% | -2.44 10.62% | N/A 7.54% | N/A 4.50% | N/A -5.22% | N/A -2.70% | N/A 17.74% | N/A 53.66% | N/A 139.08% | N/A 467.65% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.60 -2.00% | -0.55 7.63% | -0.68 -33.33% | -0.71 -28.52% | -0.66 -9.55% | -0.69 -25.20% |
| Revenue Q2Q % growth | 147.9K | -100.00% | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -23.552M 6.32% | -24.253M 2.81% | -24.638M -13.74% | -25.583M -12.95% | -26.895M -14.20% | -28.411M -17.14% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.55 -5.77% | -0.60 | 0.05 | 8.02% |
| Q1 2025 Q2Q % growth | -0.51 30.14% | -0.66 | 0.15 | 22.15% |
| Q4 2024 Q2Q % growth | -0.60 30.23% | -0.68 | 0.08 | 11.91% |
| Q3 2024 Q2Q % growth | -0.59 10.61% | -0.59 | 0.00 | -0.13% |
| Q2 2024 Q2Q % growth | -0.52 17.46% | -0.61 | 0.09 | 15.33% |
| Q1 2024 Q2Q % growth | -0.73 -25.86% | -0.86 | 0.13 | 15.28% |
| Q4 2023 Q2Q % growth | -0.86 -7.50% | -0.74 | -0.12 | -15.99% |
| Q3 2023 Q2Q % growth | -0.66 | -0.72 | 0.06 | 8.67% |
| Q2 2023 Q2Q % growth | -0.63 | -0.66 | 0.03 | 4.77% |
| Q1 2023 Q2Q % growth | -0.58 | -0.61 | 0.03 | 5.27% |
| Q4 2022 Q2Q % growth | -0.80 | -1.12 | 0.32 | 28.37% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -0.3% | 0% | 2.33% |
| Revenue | N/A | N/A | 0% | 0% |